Ranibizumab biosimilar (Lupin)

雷珠单抗生物类似药 (Lupin)

Report date: 2026/03/16 20:01:47

Base Information

Drug NameRanibizumab biosimilar (Lupin)
Drug Alias NameRanluspecLUBT-010
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsDiabetes ComplicationsChoroidal NeovascularizationRetinal Vein Occlusion +[7] 
Global Approved IndicationsDiabetes ComplicationsChoroidal NeovascularizationRetinal Vein Occlusion +[6] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2026/02/10
Country/TerritoryBulgariaUnited StatesSlovakia +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesLupin Ltd
China Registration ClassN/A

Develop Information

Active CompaniesLupin Europe GmbhLupin Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes ComplicationsChoroidal NeovascularizationRetinal Vein Occlusion +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeS01LA04
Related LinksN/A